Congenital Hyperinsulinism Treatment Market Driven by Innovations in Surgery and Drug Therapies
Congenital Hyperinsulinism (HI) is a condition where the pancreas produces excess insulin resulting in recurrent episodes of hypoglycemia in infants and children, leading to seizures or coma if not treated on time. Treatment of congenital HI requires controlling insulin levels to maintain normal blood glucose levels and prevent hypoglycemia.
The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 250.84 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024 to 2031.
Congenital HI can be treated through surgery to partially remove the insulin-secreting cells of the pancreas or through drug therapies. Congenital Hyperinsulinism Treatment Market Trends but carries risks, while drug therapy controls symptoms but may require lifelong treatment. Efforts are ongoing to develop minimally invasive surgeries and new drug therapies to effectively treat HI with minimal adverse effects. The availability of specialized treatment centers and growing awareness about HI diagnosis and management are supporting market growth.
Key Takeaways
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices.
Get More Insights On, Congenital Hyperinsulinism Treatment Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian